This paper from Naser et al supports genotype testing before treatment with anti-TNF drugs.
“Although inhibition of TNFα has shown a positive clinical outcome in some patients with CD, poor response was also found in others, which leaves those patients with severe side effects and higher susceptibility to infections. Therefore several pharmacogenetic studies have evaluated the variation of anti-TNFα treatment response among patients with CD in order to predict treatment response ultimately.”
The SNPs TNFRSF1A:rs767455 and TNFRSF1B:rs3397, which are known to affect anti-TNFα clinical outcome in CD, were associated with lower corresponding gene expression and higher MAP infection susceptibility.
